Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(4):381-382; doi:10.1093/jnci/91.4.381
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Caubet, J.-F.
Right arrow Articles by Crawford, E. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caubet, J.-F.
Right arrow Articles by Crawford, E. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 4, 381-382, February 17, 1999
© 1999 Oxford University Press

CORRESPONDENCE

Re: Quality of Life in Advanced Prostate Cancer: Results of a Randomized Therapeutic Trial

Jean-François Caubet

Correspondence to: Jean-François Caubet, M.D., 419 Plainfield Ave., Berkeley Heights, NJ 07922 (e-mail: JeanFranc@aol.com).

A link between the pharmacology of flutamide and the quality of life (QOL) of patients with metastatic prostate cancer was recently reported (1). In the National Cancer Institute/Southwest Oncology Group INT-0105 trial, better QOL scores were reported in patients receiving orchiectomy plus placebo than in patients receiving orchiectomy plus flutamide. Subjective assessments need, however, to be interpreted in the light of possible confounders of either the causes or the effects. One confounder was discussed—imbalance favoring placebo (1)—but several others need to be explored systematically.

A combined treatment was evaluated (orchiectomy plus flutamide); therefore, any difference observed with orchiectomy can be explained by either flutamide . . . [Full Text of this Article]

REFERENCES

Carol M. Moinpour, Andrea Troxel, Laura C. Lovato, Mario Eisenberger, Brent A. Blumenstein, E. David Crawford

Affiliations of authors: C. M. Moinpour, L. C. Lovato, Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA; A. Troxel, Columbia Presbyterian Cancer Center, New York, NY; M. Eisenberger, The Johns Hopkins University School of Medicine, Baltimore, MD; B. A. Blumenstein, American College of Surgeons, Chicago, IL; E. D. Crawford, University of Colorado, Denver.

Correspondence to: Carol M. Moinpour, Ph.D., Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N./MP 557, Box 19024, Seattle, WA 98109-1024.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?